Unresectable Ovarian Cancer Requires a Structured Plan of Action: A Prospective Cohort Study

Gatske M. Nieuwenhuyzen-de Boer; Malika Kengsakul; Ingrid A. Boere; Helena C. van Doorn; Heleen J. van Beekhuizen

doi:10.3390/cancers15010072

Unresectable Ovarian Cancer Requires a Structured Plan of Action: A Prospective Cohort Study

Gatske M. Nieuwenhuyzen-de Boer^*, Malika Kengsakul, Ingrid A. Boere, Helena C. van Doorn, Heleen J. van Beekhuizen

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

4 Downloads (Pure)

Abstract

Background: Patients with unresectable disease during cytoreductive surgery (CRS) for advanced-stage ovarian cancer are underreported. Knowledge of treatment and survival after surgery is limited. The aim of this study is to address the knowledge gap about postoperative treatment and survival of patients whose surgery was abandoned due to unresectability after abdominal exploration. Methods: Women with FIGO stage IIIB-IV epithelial ovarian cancer whose disease was considered to be unresectable during surgery were included in this prospective study, a post hoc analysis of the PlaComOv study. The unresectable disease was defined as the inability to achieve at least suboptimal CRS without attempted CRS after careful inspection of the entire abdomen. Preoperative clinical data, perioperative findings, postoperative treatment and survival data were analyzed. Results: From 2018 to 2020, 27 patients were included in this analysis. Treatment ranged from the cessation of treatment to one or several lines of chemotherapy with or without maintenance therapy. The median overall survival was 16 (IQR 5–21) months (95%CI 14–18). At 24 months of follow-up, four patients (15%) were alive. Conclusions: This study indicated a two-year survival of 15%. Optimal treatment strategies in terms of survival benefits are still ill-defined. Further study of this specific group of patients is warranted. We advocate an (inter)national registry of patients with unresectable cancer and comprehensive follow-up.

Original language	English
Article number	72
Journal	Cancers
Volume	15
Issue number	1
DOIs	https://doi.org/10.3390/cancers15010072
Publication status	Published - 22 Dec 2022

Bibliographical note

Funding Information:
Data were collected in The PlaComOv study. This randomized controlled trial is funded by the Netherlands Organization for Health Research and Development (ZonMw), number 843001805.

Publisher Copyright:
© 2022 by the authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers15010072Licence: CC BY

Unresectable Ovarian Cancer Requires a Structured Plan of Action A Prospective Cohort StudyFinal published version, 391 KBLicence: CC BY

Cite this

@article{789a55a3bf4541d88006e10c6eb40799,

title = "Unresectable Ovarian Cancer Requires a Structured Plan of Action: A Prospective Cohort Study",

abstract = "Background: Patients with unresectable disease during cytoreductive surgery (CRS) for advanced-stage ovarian cancer are underreported. Knowledge of treatment and survival after surgery is limited. The aim of this study is to address the knowledge gap about postoperative treatment and survival of patients whose surgery was abandoned due to unresectability after abdominal exploration. Methods: Women with FIGO stage IIIB-IV epithelial ovarian cancer whose disease was considered to be unresectable during surgery were included in this prospective study, a post hoc analysis of the PlaComOv study. The unresectable disease was defined as the inability to achieve at least suboptimal CRS without attempted CRS after careful inspection of the entire abdomen. Preoperative clinical data, perioperative findings, postoperative treatment and survival data were analyzed. Results: From 2018 to 2020, 27 patients were included in this analysis. Treatment ranged from the cessation of treatment to one or several lines of chemotherapy with or without maintenance therapy. The median overall survival was 16 (IQR 5–21) months (95%CI 14–18). At 24 months of follow-up, four patients (15%) were alive. Conclusions: This study indicated a two-year survival of 15%. Optimal treatment strategies in terms of survival benefits are still ill-defined. Further study of this specific group of patients is warranted. We advocate an (inter)national registry of patients with unresectable cancer and comprehensive follow-up.",

author = "{Nieuwenhuyzen-de Boer}, {Gatske M.} and Malika Kengsakul and Boere, {Ingrid A.} and {van Doorn}, {Helena C.} and {van Beekhuizen}, {Heleen J.}",

note = "Funding Information: Data were collected in The PlaComOv study. This randomized controlled trial is funded by the Netherlands Organization for Health Research and Development (ZonMw), number 843001805. Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = dec,

day = "22",

doi = "10.3390/cancers15010072",

language = "English",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - Unresectable Ovarian Cancer Requires a Structured Plan of Action

T2 - A Prospective Cohort Study

AU - Nieuwenhuyzen-de Boer, Gatske M.

AU - Kengsakul, Malika

AU - Boere, Ingrid A.

AU - van Doorn, Helena C.

AU - van Beekhuizen, Heleen J.

N1 - Funding Information: Data were collected in The PlaComOv study. This randomized controlled trial is funded by the Netherlands Organization for Health Research and Development (ZonMw), number 843001805. Publisher Copyright: © 2022 by the authors.

PY - 2022/12/22

Y1 - 2022/12/22

N2 - Background: Patients with unresectable disease during cytoreductive surgery (CRS) for advanced-stage ovarian cancer are underreported. Knowledge of treatment and survival after surgery is limited. The aim of this study is to address the knowledge gap about postoperative treatment and survival of patients whose surgery was abandoned due to unresectability after abdominal exploration. Methods: Women with FIGO stage IIIB-IV epithelial ovarian cancer whose disease was considered to be unresectable during surgery were included in this prospective study, a post hoc analysis of the PlaComOv study. The unresectable disease was defined as the inability to achieve at least suboptimal CRS without attempted CRS after careful inspection of the entire abdomen. Preoperative clinical data, perioperative findings, postoperative treatment and survival data were analyzed. Results: From 2018 to 2020, 27 patients were included in this analysis. Treatment ranged from the cessation of treatment to one or several lines of chemotherapy with or without maintenance therapy. The median overall survival was 16 (IQR 5–21) months (95%CI 14–18). At 24 months of follow-up, four patients (15%) were alive. Conclusions: This study indicated a two-year survival of 15%. Optimal treatment strategies in terms of survival benefits are still ill-defined. Further study of this specific group of patients is warranted. We advocate an (inter)national registry of patients with unresectable cancer and comprehensive follow-up.

AB - Background: Patients with unresectable disease during cytoreductive surgery (CRS) for advanced-stage ovarian cancer are underreported. Knowledge of treatment and survival after surgery is limited. The aim of this study is to address the knowledge gap about postoperative treatment and survival of patients whose surgery was abandoned due to unresectability after abdominal exploration. Methods: Women with FIGO stage IIIB-IV epithelial ovarian cancer whose disease was considered to be unresectable during surgery were included in this prospective study, a post hoc analysis of the PlaComOv study. The unresectable disease was defined as the inability to achieve at least suboptimal CRS without attempted CRS after careful inspection of the entire abdomen. Preoperative clinical data, perioperative findings, postoperative treatment and survival data were analyzed. Results: From 2018 to 2020, 27 patients were included in this analysis. Treatment ranged from the cessation of treatment to one or several lines of chemotherapy with or without maintenance therapy. The median overall survival was 16 (IQR 5–21) months (95%CI 14–18). At 24 months of follow-up, four patients (15%) were alive. Conclusions: This study indicated a two-year survival of 15%. Optimal treatment strategies in terms of survival benefits are still ill-defined. Further study of this specific group of patients is warranted. We advocate an (inter)national registry of patients with unresectable cancer and comprehensive follow-up.

UR - http://www.scopus.com/inward/record.url?scp=85146024433&partnerID=8YFLogxK

U2 - 10.3390/cancers15010072

DO - 10.3390/cancers15010072

M3 - Article

AN - SCOPUS:85146024433

SN - 2072-6694

VL - 15

JO - Cancers

JF - Cancers

IS - 1

M1 - 72

ER -

Unresectable Ovarian Cancer Requires a Structured Plan of Action: A Prospective Cohort Study

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this